An unbiased transcriptome-wide RNA targeted sequencing discovered that ALL patient leukemic cells with relatively high levels of opioid receptor μ1 (OPRM1) are more sensitive to asparaginase treatment compared to OPRM1-depleted leukemic cells [87]. The gene discussed is OPRM1; the disease is acute lymphoblastic leukemia.